Provide transparent information quickly by Genexine

Accurate and fast delivery of key events and news of growing Genexine

Press Release

Genexine’s Cervical cancer therapeutic vaccine abstract released at ASCO 2021
2021.05.20

[2021/05/20] Genexine, inc. (KOSDAQ: 095700), a Korean biopharmaceutical company, announced that interim result of GX-188E and Keytruda®(Pembrolizumab) combination therapy’s clinical phase 2 study (KEYNOTE-567/GX-188E-005) was released on 19th at 5pm at ASCO 2021 webpage (https://conferences.asco.org).

The interim result shows 5 patients with complete remission and 10 patients with partial remission in which case size of target lesion decrease 30% from the conducted study averaged duration of 6.2 months, out of total 48 patients who are 16 or 18 type HPV induced recurrent/metastatic advanced cervical cancer.

The patient group with combination therapy with GX-188E and Keytruda® showed ORR of 31.3%, especially it showed ORR as high as 48% in case of the patient group with most common cervical cancer type which is PD-L1 positive, HPV type 16 and squamous cell carcinoma. Additionally, PFS was 4.1 months and OS was 16.7 months which is highly upgraded data when it is compared to the Keytruda®’s monotherapy.

In terms of safety, the company again evaluated high safeness of the DNA vaccine platform since 17 patients showed grade 1,2 light adverse events and only 2 patients with 3,4 adverse events out of 52 patients.

ASCO 2021 will be held online from 4th to 8th of June, Genexine will give oral presentation at 9 am June 4th with more advanced result than the released abstract contents.

GX-188E is currently in phase 2 clinical study for 60 patients in Korea, co-develop and support from Korea Drug Development Fund(KDDF) who aims to support for successful global new drug development.